Introduction
KCNQ channels (also named Kv7) are voltagedependent potassium channels composed of five different KCNQ subunits (KCNQ1-5 or Kv7.1-7.5). KCNQ2 and KCNQ3 channels are expressed in neuronal tissue, most often as heterodimers (KCNQ2/3) (Jentsch, 2000) . An association between KCNQ2/3 channels and drug reward is apparent, but a specific interaction has not been shown. KCNQ2/3 channels are densely expressed on dopamine neurons in the ventral tegmental area (VTA) (Dalby-Brown et al., 2006; Koyama and Appel, 2006) . KCNQ2/3 activation reduces midbrain dopamine neuronal excitability and attenuates the locomotor activation and elevation in extracellular dopamine in the nucleus accumbens produced by acute psychostimulant exposure (Hansen et al., , 2007 Sotty et al., 2009) . On the basis of KCNQ2/3 and dopamine interactions, we tested the hypothesis that flupirtine (FLU), a KCNQ2/3 agonist, would inhibit conditioned place preference (CPP) produced by cocaine.
Methods

Subjects and drugs
Male Sprague-Dawley rats (270-300 g) (Harlan Laboratories, Indianapolis, Indiana, USA) were housed two per cage and maintained on a 12-h light/dark cycle. Food and water were freely available, except during behavioral testing. Animal use procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and Temple University Guidelines for the Care of Animals. Cocaine hydrochloride (Sigma Aldrich; St. Louis, Missouri, USA) and FLU maleate salt (AstaTech, Bristol, Pennsylvania, USA) were injected intraperitoneally.
Conditioned place preference
CPP experiments were conducted as described (Gregg et al., 2015) . Time spent in each compartment was recorded during a 30 min pretest and the 'least-preferred compartment' was designated as the drug-paired compartment. During a 4-day conditioning phase, rats were injected with cocaine (15 mg/kg) and confined to their least-preferred side and, 4 h later, were injected with saline and confined to the opposite side. Control animals were conditioned with saline in each compartment. Thirty minutes before cocaine or saline, rats were pretreated with FLU (20 mg/ kg) or saline. One day following conditioning (post-test), rats were placed back into the chambers, with free access to both sides for 30 min, and the time spent in each compartment was determined. Experiments were repeated with lower doses of FLU (2.5, 10 mg/kg).
Locomotor experiments
Locomotor activity was recorded using a Digiscan DMicro System (AccuScan Instruments, Inc., Columbus, Ohio, USA) as described (Gregg et al., 2015) . Each rat was placed individually into an activity chamber and allowed to acclimate for 60 min. Rats were then injected with FLU (20 mg/kg) or saline, followed 30 min later with cocaine (15 mg/kg) or saline.
Statistical analyses
Statistical significance was set at P value less than 0.05. CPP data were analyzed by two-way analysis of variance (ANOVA) with the between-subject factors of FLU pretreatment and cocaine treatment, followed by Bonferroni post-hoc tests. Time-course locomotor data were analyzed by two-way ANOVA (treatment × time), followed by Bonferroni post-hoc tests to compare treatment effects at each time point. Cumulative locomotor data were analyzed by one-way ANOVA, followed by Bonferroni post-hoc tests.
Results
Flupirtine pretreatment reduces the development of cocaine place preference Two-way ANOVA showed a significant effect of cocaine treatment [F(1,24) = 16.39, P < 0.001], but not of FLU pretreatment [F(1,24) = 3.54, NS] (Fig. 1) . Rats treated with 15 mg/kg cocaine (SAL COC) produced greater place preference than saline-treated controls (SAL SAL) (P < 0.01). For rats treated with cocaine (15 mg/kg), pretreatment with FLU (20 mg/kg) (FLU COC) during conditioning resulted in reduced place preference compared with saline pretreatment (SAL COC) (P < 0.05). Effects of different doses of FLU (2.5, 10, 20 mg/kg) on CPP produced by cocaine (15 mg/kg) are presented in the (Fig. 2) . Rats treated with 15 mg/kg cocaine (SAL COC) showed greater cumulative total activity counts than drug-naive rats (SAL SAL) (P < 0.05). For cocaine-treated rats, pretreatment with FLU (20 mg/kg) (FLU COC) decreased the total activity counts compared with saline pretreatment (SAL COC) (P < 0.05). In cocaine-naive rats, the total activity counts were not different in rats pretreated with 20 mg/kg (FLU SAL) or saline (SAL SAL) (P > 0.05) (Fig. 2) .
Discussion
A likely mechanism underlying the efficacy of FLU against cocaine CPP is KCNQ2/3 channel activation in the VTA, which counteracts the normal elevation in extracellular dopamine in the nucleus accumbens that contributes toward the rewarding effects of cocaine (Cervo and Samanin, 1995) . KCQNQ2/3 activation reduces the firing frequency of VTA dopaminergic neurons in vitro and in vivo and inhibits striatal dopamine synthesis and c-Fos expression . In our experiments, FLU also reduced locomotor activation caused by a dose of cocaine that is rewarding. KCNQ2/3-dopamine interactions have been identified in the context of locomotor activity as systemically injected retigabine reduces locomotor activation produced by acute exposure to cocaine, methylphenidate, or amphetamine (Hansen et al., 2007; Sotty et al., 2009) . A role for N-methyl-D-aspartate (NMDA) receptors cannot be discounted as FLU antagonizes NMDA receptors and NMDA receptor antagonists reduce the development of cocaine CPP (Cervo and Samanin, 1995) .
In a biased CPP assay, the compartmental shift to the drug-paired side can be interpreted as a positive rewarding effect or decreased aversion because of anxiolytic effects. We used a dose of cocaine (15 mg/kg) here that produces robust place conditioning in both unbiased and biased procedures (Galaj et al., 2015) . Furthermore, FLU by itself did not produce a compartmental shift. In this context, the most likely explanation for the efficacy of FLU is inhibition of cocaine reward, although anxiolytic effects cannot be excluded because of its GABAenhancing activity (Treven et al., 2015) .
Conclusion
KCNQ2/3 research has focused almost exclusively on epilepsy, pain, inflammation, fibromyalgia, and arterial vasospasm and led to the development of KNCQ2/3 channel openers as approved medications. Although both FLU and retigabine can act through multiple mechanisms and have been reported to have mild rewarding effects themselves, the present data point toward studying the effects of KCNQ2/3 agonists on psychostimulant reward, reinforcement, and relapse.
